Clarity Pharmaceuticals (FRA:1F4) Volatility: N/A% (As of Jul. 07, 2026)


FRA:1F4 Clarity Pharmaceuticals Ltd FRA:1F4
13 GF Score
Price €1.64
! 2 Warning Signs
View Full Analysis

What is Clarity Pharmaceuticals Volatility?

Clarity Pharmaceuticals FRA:1F4 +25.19% 13 Volatility is N/A% as of Jul. 07, 2026. GuruFocus rates FRA:1F4 with a GF Score™ of 13/100. The stock has 2 warning signs investors should review.

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

Clarity Pharmaceuticals does not have enough data to calculate Volatility.

Clarity Pharmaceuticals  (FRA:1F4) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Clarity Pharmaceuticals Volatility Related Terms

FRA:1F4
13GF Score
Clarity Pharmaceuticals Ltd FRA:1F4
Volatility is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clarity Pharmaceuticals  (FRA:1F4) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * √12
=√ 1/(n-1) ∑(Ri - R')^2 * √12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Volatility →
What does a Volatility of N/A% mean?
Clarity Pharmaceuticals (FRA:1F4) has a Volatility of N/A% as of Jul. 07, 2026. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Clarity Pharmaceuticals and its competitors.
Is Clarity Pharmaceuticals' Volatility too high?
Clarity Pharmaceuticals' current Volatility is N/A%. Overall, Clarity Pharmaceuticals has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Clarity Pharmaceuticals' Volatility compare to VRTX and REGN?
Clarity Pharmaceuticals' Volatility of N/A% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Volatility for a Biotechnology company?
A good Volatility depends on the Biotechnology industry context. However, Volatility should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Volatility mean?
A high Volatility can signal that a stock is expensive relative to its fundamentals. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Clarity Pharmaceuticals and its competitors. Clarity Pharmaceuticals's current Volatility is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clarity Pharmaceuticals stock overvalued right now?
Clarity Pharmaceuticals (FRA:1F4) has a current Volatility of N/A%. The current Volatility is N/A%. Clarity Pharmaceuticals' overall GF Score™ is 13/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Volatility calculated?
Volatility is calculated from a company's financial statements. For Clarity Pharmaceuticals (FRA:1F4), the current Volatility is N/A% as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Clarity Pharmaceuticals Business Description

Other Exchanges CLRPF:USACU6:Australia
Address 2-4 Cornwallis Street, Suite 212a, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, using its SAR Technology platform. Clarity's Targeted Copper Theranostic (TCT) platform of products utilize pairing of copper isotopes, specifically copper-64 (Cu-64 or 64Cu) for imaging and copper-67 Cu-67 or 67Cu) for therapy, which delivers accuracy and precision in the treatment of a range of cancers. The company's clinical development pipeline includes SAR-bisPSMA, SAR-Bombesin, and Sartate, in their different stages of development for the diagnosis and/or treatment of various cancers. Clarity operates in a single segment, which is the development of radiopharmaceuticals. Geographically, it operates in Australia and the United States.
13GF Score

Get the complete analysis for FRA:1F4

Volatility is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.64
Price